Physician profile
Mildred Clifton
NPI 1679521405
$92,244.72
in general payments reported to CMS, 2019-2025
30 companies · $6,974 in 2025
The $6,974 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,570 · 2020: $13K · 2021: $21K · 2022: $22K · 2023: $18K · 2024: $8,577 · 2025: $6,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $5,566 · Education: $95.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,428.90 |
| Food and Beverage | $5,566.23 |
| Education | $95.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $52,950.93 | 2019-2022 | |
| Abbvie INC. | $33,384.40 | 2019-2025 | Botox, Skyrizi, Rinvoq |
| Lilly USA, LLC | $1,208.91 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $772.83 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $460.21 | 2019-2025 | Odomzo, Blu-U |
| Galderma Laboratories, L.P. | $432.78 | 2019-2022 | |
| Pfizer INC. | $419.29 | 2019-2024 | |
| Revance Therapeutics, INC. | $396.61 | 2024-2025 | Daxxify |
| Genzyme Corporation | $387.62 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $265.63 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $221.89 | 2019-2025 | |
| Leo Pharma INC. | $173.67 | 2024-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $155.10 | 2019-2025 | |
| Ucb, INC. | $138.90 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $138.21 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $121.63 | 2019-2024 | Otezla |
| Endo Pharmaceuticals INC. | $98.79 | 2021 | |
| Merz North America, INC. | $92.47 | 2024 | |
| Arcutis Biotherapeutics, INC. | $61.62 | 2023-2025 | Zoryve |
| Dexcom, INC. | $50.73 | 2025 | Dexcom G6 Transmitter |
| Dusa Pharmaceuticals, INC. | $46.65 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.97 | 2019-2021 | |
| Celgene Corporation | $42.39 | 2019 | |
| Kyowa Kirin, INC. | $41.30 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $38.69 | 2019 | |
| Dermira, INC. | $34.34 | 2019 | |
| Almirall LLC | $23.24 | 2021 | |
| Incyte Corporation | $20.50 | 2024 | Opzelura |
| Vyne Pharmaceuticals INC. | $19.13 | 2020 | |
| Organon LLC | $3.29 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mildred Clifton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.